Clinical Trials on Pulmonary Hypertension in Russian Federation

Total 361 results

GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
AstraZeneca

Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS) (REACT)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Austria, Belgium, Germany, Greece, Russian Federation, Australia, Brazil, Canada, Denmark, France, Hungary, Israel, Italy, Netherlands, Poland, Slovakia, South Africa, Spain, Turkey, United Kingdom
GlaxoSmithKline

Completed

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Russian Federation, Ukraine
Global Alliance for TB Drug Development

Completed

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant Tuberculosis

Tanzania, Georgia, Russian Federation, Brazil, Malaysia, Philippines, South Africa, Uganda
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Hypertension

United States, Colombia, Spain, Germany, Taiwan, Russian Federation, Argentina, France, Italy, Korea, Republic of, Japan, Greece
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

Hypertension

United States, Russian Federation, South Africa, Dominican Republic, India
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, Germany, United Kingdom, China, Philippines, Italy, Chile, Taiwan, Thailand, France, Puerto Rico, Israel, Peru, Colombia, Poland, Brazil, Russian Federation, Romania, Greece
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Poland, Romania, Russian Federation, Ukraine, Taiwan, Bulgaria, South Africa, Korea, Republic of
Galecto Biotech AB
Syneos Health; bioRASI, LLC

Completed

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

United States, Spain, Israel, France, United Kingdom, Russian Federation, Australia, Italy, Germany, Canada, Belgium, Georgia, Ireland, Poland, Ukraine
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Germany, Canada, Spain, Russian Federation, United States, Belgium, France, Greece, Sweden, Norway, Turkey, Australia, Netherlands, United Kingdom
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Korea, Republic of, United States, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Romania, Russian Federation, Slovakia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Hypertension

United States, Spain, Philippines, Guatemala, Russian Federation, Argentina, Puerto Rico
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
Boehringer Ingelheim

Completed

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, France, Greece, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Taiwan, Turkey, Ukraine, United Kingdom
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Austria, Canada, Spain, United States, Finland, Italy, Russian Federation, United Kingdom, New Zealand, Australia, France, Greece, Ireland, Netherlands, South Africa
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
Boehringer Ingelheim

Completed

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Spain, United States, Canada, Korea, Republic of, Australia, Italy, United Kingdom, Germany, China, Finland, Denmark, Netherlands, Greece, Argentina, Austria, Chile, Czechia, Hungary, Japan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Hypertension

Spain, Italy, Netherlands, United States, Denmark, Taiwan, Argentina, Germany, Russian Federation, Slovakia, Canada, Hungary, Latvia, Lithuania, Poland, Finland, France, Sweden
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
GlaxoSmithKline

Terminated

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, France, Germany, Poland, Romania, Russian Federation, Spain, United States, Netherlands, Sweden, Korea, Republic of, Canada, United Kingdom, Italy, Mexico
Boehringer Ingelheim

Completed

Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Switzerland, Turkey, Ukraine, United Kingdom
AbbVie

Completed

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States, Australia, Canada, Denmark, France, Germany, Israel, New Zealand, Philippines, Poland, Russian Federation, United Kingdom
Biogen

Terminated

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis (SPIRIT)

Idiopathic Pulmonary Fibrosis

United States, Italy, Belgium, Czechia, Russian Federation, Korea, Republic of, Australia, France, Israel, Spain, Poland, Netherlands, Denmark, Greece, Argentina, Chile, United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Pulmonary Fibrosis

United States, Canada, Chile, China, Finland, France, Germany, Greece, India, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, Spain, Turkey
Boehringer Ingelheim

Completed

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Hungary, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan
Sanofi
Regeneron Pharmaceuticals

Completed

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (BOREAS)

Chronic Obstructive Pulmonary Disease

Spain, Argentina, China, Mexico, Canada, Ukraine, Israel, Italy, Czechia, Korea, Republic of, Bulgaria, Chile, Denmark, Finland, Germany, Hungary, Japan, Poland, Romania, Russian Federation, Slovakia, Sweden, Turkey, United States
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
GlaxoSmithKline

Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Ukraine, United States, Estonia, South Africa, Sweden, Norway, Russian Federation, Korea, Republic of
GlaxoSmithKline

Completed

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

Pulmonary Disease, Chronic Obstructive

United States, Australia, Canada, France, Poland, Russian Federation, Spain, Estonia, Belgium, Peru, Sweden, Greece, Mexico, Norway, Italy, Czechia
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Guatemala, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian... and more
Boehringer Ingelheim

Completed

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Hypertension

United States, Bulgaria, China, France, Georgia, Korea, Republic of, Romania, Russian Federation
Boehringer Ingelheim

Completed

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Norway, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Boehringer Ingelheim

Completed

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more

Clinical Trials on Pulmonary Hypertension in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations